EverSea Medicines to Acquire Hasten Biopharmaceuticals

Why It Matters

The transaction instantly expands Everest’s product portfolio and market reach in a high‑growth chronic‑disease segment, positioning the company for stronger revenue streams and competitive advantage across Asia‑Pacific.

Key Takeaways

• $250 million acquisition adds 14 chronic‑disease products in Asia‑Pacific
• Hasten posted $82 million revenue and $27 million EBITDA in 2025
• Deal includes $29 million refundable yuan deposit to Everest
• Payments: $150 million at close, $50 million in 2028, $50 million in 2029
• Acquisition expands Everest’s commercial reach from China to Asia‑Pacific

Pulse Analysis

Everest Medicines’ move to acquire Hasten Biopharmaceuticals marks a decisive step into the broader Asia‑Pacific market, where chronic‑disease therapeutics are experiencing double‑digit growth. By securing MAH rights and trademarks for 14 established products, Everest can leverage existing regulatory approvals and distribution networks, shortening time‑to‑market for its own pipeline candidates such as Nefecon and Xerava. The deal also aligns with a regional shift toward integrated care models that favour multi‑product portfolios capable of addressing metabolic, cardiovascular, and renal conditions.

Financially, the $250 million price tag reflects a modest premium over Hasten’s 2025 EBITDA of $27.27 million, implying an enterprise multiple near 9x—reasonable for a company with proven revenue streams and a strong chronic‑care focus. The staggered payment schedule, with $150 million due at closing and two $50 million instalments in 2028 and 2029, mitigates cash‑flow risk for Everest while tying future payouts to performance milestones. The additional refundable yuan deposit of $29.2 million underscores the parties’ confidence in meeting regulatory and commercial conditions, and it provides Everest with immediate working capital.

Strategically, the acquisition bolsters Everest’s ambition to become a pan‑Asian leader in chronic‑disease treatment. It complements the recent exclusive licence with Micot for MT1013, expanding Everest’s pipeline depth and geographic coverage. As Asian regulators increasingly prioritize reimbursement pathways for high‑burden diseases, Everest’s enlarged portfolio and enhanced commercial infrastructure position it to capture a larger share of a market projected to exceed $150 billion by 2030. Competitors will need comparable scale or strategic partnerships to keep pace, making this deal a potential catalyst for further consolidation in the region’s pharmaceutical landscape.